We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevention of Asthma Relapse After Discharge From Emergency (PARADE)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00326053
First Posted: May 16, 2006
Last Update Posted: January 24, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
May 12, 2006
May 16, 2006
January 24, 2011
May 2006
Not Provided
Time to first asthma relapse
Same as current
Complete list of historical versions of study NCT00326053 on ClinicalTrials.gov Archive Site
  • Mean use of reliever medication
  • Asthma Control Questionnaire (ACQ) score
  • Complete AE and SAE collection
Same as current
Not Provided
Not Provided
 
Prevention of Asthma Relapse After Discharge From Emergency
A Comparison of Budesonide/Formoterol Turbuhaler® 160/4.5 µg 2 Inhalations BID Plus as Needed to Budesonide Turbuhaler® 320 µg 2 Inhalations BID Plus Terbutaline Turbuhaler® 0.4 mg as Needed for the Prevention of Asthma Relapse
The purpose of this study is to compare the Symbicort® Turbuhaler® to both Pulmicort® Turbuhaler® and Bricanyl® Turbuhaler® for the treatment of asthma after discharge from the emergency room
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Asthma
Drug: Budesonide/formoterol
Other Name: Symbicort
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
600
May 2007
Not Provided

Inclusion Criteria:

  • 18 - 65 years of age
  • Presenting at a study emergency department with an asthma exacerbation

Exclusion Criteria:

  • Admission to hospital
  • Patients receiving more than 2000 µg/day of beclomethasone equivalent inhaled corticosteroids (1000 µg/day fluticasone or 1600 µg/day budesonide)
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00326053
D5890L00017
PARADE
Not Provided
Not Provided
Not Provided
Not Provided
AstraZeneca
Not Provided
Study Director: Gloria Jordana, MD AstraZeneca
Principal Investigator: Brian Rowe, MD University of Alberta
AstraZeneca
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP